The webinar will be the occasion for the launch of a White Paper entitled “Anatomy of a failure to launch: A review of barriers to generic and biosimilar entry and the use of competition law”.

The discussion will focus on how to make sure that current barriers to generic and biosimilar medicines market entry can be tackled in order to avoid any unnecessary delays to patient access.

The launch of the White Paper aims to inform the current debate around the IP strategy in the context of the broader Pharmaceutical Strategy of the European Commission.  Discussions will include how to deal with IP and patent quality, patent linkage, pricing strategies, as well as ways to ensure effective competition in the pharmaceutical market.